Resectable Squamous Cell Carcinoma of Oral Cavity
1 clinical trials · Condition
◉ Watch Resectable Squamous Cell Carcinoma of Oral Cavity
| Record | Firm | Date |
|---|---|---|
| Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity (NCT02993991) | University Health Network, Toronto | 2017-10-10 |
Track Resectable Squamous Cell Carcinoma of Oral Cavity automatically
Every clearance here is in the API, with alerts when new ones post.